Location History:
- Hamburg, DE (2014 - 2017)
- Baltimore, MD (US) (2016 - 2021)
Company Filing History:
5 out of 3,687 
5 out of 2,009 
1 out of 1,035 
Years Active: 2014-2021
Title: Innovations in Cancer Research: The Contributions of Inventor Philipp Angenendt
Introduction
Philipp Angenendt, an esteemed inventor hailing from Baltimore, MD, has made significant strides in the field of cancer research, particularly concerning malignant gliomas. With a total of six patents to his name, he has contributed to groundbreaking discoveries that enhance our understanding of cancer genetics.
Latest Patents
Among his notable patents, Philipp's most recent work focuses on genetic alterations in isocitrate dehydrogenase and other genes linked to malignant glioma. His research reveals mutations in the R132 residue of isocitrate dehydrogenase 1 (IDH1) that are prevalent in grade II and III astrocytomas and oligodendrogliomas, as well as glioblastomas that arise from these lower-grade lesions. Additionally, for tumors without IDH1 mutations, similar mutations were identified in the R172 residue of the closely related IDH2 gene. These findings are pivotal as they provide crucial insights into the pathogenesis and diagnosis of malignant gliomas.
Career Highlights
Philipp Angenendt has collaborated with prominent research institutions to further his work. He has held positions at esteemed universities such as The Johns Hopkins University and Duke University. His dedication to advancing cancer research has established him as a leading figure in the scientific community.
Collaborations
Throughout his career, Philipp has had the opportunity to work alongside esteemed colleagues, including renowned cancer researchers Bert Vogelstein and Kenneth W. Kinzler. Collaborating with such distinguished experts has further propelled his innovative contributions to the field.
Conclusion
In summary, Philipp Angenendt's work as an inventor has significantly impacted the realm of cancer research, particularly through his patents related to genetic alterations in malignant gliomas. His collaborations with prestigious institutions and fellow researchers continue to pave the way for advancements in cancer diagnosis and treatment.